Dr. Anna Vilgelm is a cancer biologist with experience in basic and translational studies. The main focus of Dr. Vilgelm's research is on pre-clinical development of effective strategies for metastatic cancer treatment. Currently, Vilgelm laboratory investigates ways to stimulate anti-tumor immunity by inducing “hot”, immune-cell enriched, tumor micro-environment. Specifically, modulation of molecular mechanisms controlling tumor secretome in explored. In addition Dr. Vilgelm's research team is developing personalized medicine approaches to induce synthetic lethality in tumor cells using rational drug combinations. They utilize a variety of pre-clinical research models including 3D organoid cultures of patient's tumor cells and humanized patient-derived models. Our ultimate goal is to develop new therapeutic approaches to stimulate anti-tumor immunity that prevents tumor relapses resulting in long lasting disease control.